Publications by authors named "M A Molina-Vila"
Background: ROS1 fusion is a relatively low prevalence (0.6-2.0%) but targetable driver in lung adenocarcinoma (LUAD).
View Article and Find Full Text PDFArticle Synopsis
- LCINS accounts for 20% of lung cancer cases, with the study focusing on the molecular profile of driver genes in Brazilian patients who never smoked.
- The investigation involved studying mutational and gene fusion status in 119 lung adenocarcinomas using advanced sequencing techniques, alongside genetic ancestry analysis.
- Results showed high mutation rates in genes like EGFR and TP53, with significant findings on ancestry influencing mutation patterns, and highlighted that a large percentage of patients have potential targets for effective treatment.
Background/aim: Extracellular vesicle DNA (EV-DNA) has emerged as a novel biomarker for tumor mutation detection using liquid biopsies, exhibiting biological advantages compared to cell-free DNA (cfDNA). This study assessed the feasibility of EV-DNA and cfDNA extraction and sequencing in old serum samples of patients with breast cancer (BC).
Patients And Methods: A total of 28 serum samples of 27 patients with corresponding clinical information were collected between 1983 and 1991.
Background: KRAS-mutant non-small cell lung cancer (NSCLC) shows a relatively low response rate to chemotherapy, immunotherapy and KRAS-G12C selective inhibitors, leading to short median progression-free survival, and overall survival. The MET receptor tyrosine kinase (c-MET), the cognate receptor of hepatocyte growth factor (HGF), was reported to be overexpressed in KRAS-mutant lung cancer cells leading to tumor-growth in anchorage-independent conditions.
Methods: Cell viability assay and synergy analysis were carried out in native, sotorasib and trametinib-resistant KRAS-mutant NSCLC cell lines.